Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | GRK2 | P25098 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MIF | P14174 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5994924 | 1.00 | POLB (0.56) | POLBAPAF1GRK2APOBEC3GRAB9A | |
| SCHEMBL28564102 | 0.85 | NPC1 (0.65) | RAB9ANPC1SMN1; SMN2MIFCYP2C19 | |
| SCHEMBL3326724 | 0.83 | LMNA (0.53) | RAB9ANPC1SMN1; SMN2MIF | |
| SCHEMBL6853296 | 0.83 | POLB (0.53) | POLBAPAF1GRK2APOBEC3GRAB9A | |
| SCHEMBL6021765 | 0.83 | POLB (0.56) | POLBAPAF1GRK2APOBEC3GRAB9A | |
| SCHEMBL5997363 | 0.83 | APAF1 (0.53) | POLBAPAF1GRK2APOBEC3GRAB9A | |
| SCHEMBL4951608 | 0.83 | LMNA (0.53) | RAB9ANPC1SMN1; SMN2MIF | |
| SCHEMBL14183637 | 0.83 | MIF (0.54) | POLBRAB9ANPC1MIFCYP2C19 | |
| SCHEMBL3326726 | 0.83 | LMNA (0.53) | RAB9ANPC1SMN1; SMN2MIF | |
| SCHEMBL14183734 | 0.83 | MIF (0.44) | RAB9ANPC1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998390-B2 | Oxolide antibacterials | ABBVIE INC. | 2006-02-14 | — | — | US | claimed |
| EP-1579864-A1 | Oxolide antibacterials | ABBOTT LABORATORIES (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040014688-A1 | Oxolide antibacterials | ABBVIE INC. | 2004-01-22 | — | — | US | claimed |
| EP-1251128-B1 | Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists | WARNER LAMBERT CO (US) | 2006-12-06 | — | — | EP | disclosed |
| US-7026321-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-6998390-B2 | Oxolide antibacterials | ABBVIE INC. | 2006-02-14 | — | — | US | disclosed |
| EP-1583751-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES | CV THERAPEUTICS, INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1579864-A1 | Oxolide antibacterials | ABBOTT LABORATORIES (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1499326-A1 | OXOLIDE ANTIBACTERIALS | Abbott Laboratories (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040186109-A1 | piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction | CV THERAPEUTICS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004069818-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES | CV THERAPEUTICS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040014688-A1 | Oxolide antibacterials | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003090760-A1 | OXOLIDE ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186109-A1 | piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction | KCNJ2, PPARA, PPARD | POLB 2183/4885APAF1 3873/4885GRK2 841/4885 |
| US-20040014688-A1 | Oxolide antibacterials | OGFOD1, PGLS, OXER1 | POLB 220/4885APAF1 1109/4885GRK2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.